Head-to-head evidence
Recaticimab vs Tafolecimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: PCSK9 · full Atherosclerotic Cardiovascular Disease pipeline
Recaticimab
Developed by Jiangsu Hengrui Pharmaceuticals
NCT04849000 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 709 participants, using percentage change in LDL cholesterol as the primary measure. The sponsor reports statistically significant LDL reductions of 45 to 53 percentage points versus placebo across all three dosing regimens.
Tafolecimab · Sintbilo
Marketed by Innovent Biologics
NCT04289285 · Phase 3 · completed
This randomized, quadruple-blind, placebo-controlled trial enrolled 804 participants and met its primary endpoint: LDL cholesterol fell by roughly 57 to 65 percentage points more than placebo across both dosing regimens, a highly statistically significant result.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Recaticimab's landscape · Tafolecimab's landscape